Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Genomic determinants and differences of primary and secondary plasma cell leukemia

Mehmet Samur, Hamza Hassan, Qi Yan, Sarah Parker, Prashant Singh, Megan Schaefer, Kristina Slemmer, Kimberly Celotto, Ian Lund, Hailey Battaglia, Annmarie Nowak, Linda Lutgen, Saeed Daneshmandi, Kenan Onel, Philip McCarthy, Nikhil Munshi, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (Supplement 1): 7469.

https://doi.org/10.1182/blood-2025-7469

Published: 2025

Journal Articles

Peripheral blood immune profiling in newly diagnosed multiple myeloma: Associations with MRD status and high-risk cytogenetics

Anuja Abhyankar, Janine Joseph, Nour Nassour, Jas Virk, Sarah Parker, Hemn Mohammadpour, Joseph Tario, Philip McCarthy, Jens Hillengass

Blood (2025) 146 (Supplement 1): 7464.

https://doi.org/10.1182/blood-2025-7464

Published: 2025

Journal Articles

The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial

Blood (2025) 146 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2025-1033

Published: 2025

Journal Articles

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Janine Joseph, Joseph Tario, Han Yu, Sarah Parker, Ian Lund, Kristina Slemmer, Hailey Battaglia, Megan Schaefer, Kimberly Celotto, Philip McCarthy, Hamza Hassan, Hemn Mohammadpour, Jens Hillengass

Blood (2025) 146 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2025-1411

Published: 2025

Journal Articles

Galectin-3 in host murine models lessens the severity of graft-versus-host disease by preserving intestinal stem cells irrespective of gut microbiota composition

Nour Nassour, JeeEun Choi, Qi Yan, Eduardo Cortes Gomez, Jianmin Wang, Jingxin Qiu, Philip McCarthy, Hemn Mohammadpour

Blood (2025) 146 (Supplement 1): 4083.

https://doi.org/10.1182/blood-2025-4083

Published: 2025

Journal Articles

Circulating immune profile in patients with amyloidosis

Janine Joseph, Joseph Tario, Han Yu, Philip McCarthy, Hamza Hassan, Sarah Parker, Megan Schaefer, Hailey Battaglia, Hemn Mohammadpour, Jens Hillengass

Blood (2025) 146 (Supplement 1): 5748.

https://doi.org/10.1182/blood-2025-5748

Published: 2025

Journal Articles

Germline genetic variants and post-HCT cytokine/chemokine milieu may identify those at higher risk of primary graft failure after allogeneic hematopoietic cell transplantation, a blood and marrow transplant clinical trials network (BMT CTN) study

Kirsten Williams, Jennifer Holter-Chakrabarty, Sara Vesely, Marie Gordon, Ashwin Koppayi, Yvonne Suessmuth, Iskra Pusic, John McCarty, Philip McCarthy, Asad Bashey, Gregory Yanik, Michelle Schoettler, Valerie Stewart, Sarita Layton, Stephen Spellman, Wael Saber, Christopher Porter, Lucy Godley

Blood (2025) 146 (Supplement 1): 4209.

https://doi.org/10.1182/blood-2025-4209

Published: 2025

Journal Articles

Right time: stopping multiple myeloma maintenance

Philip McCarthy, Hemn Mohammadpour

Blood (2025) 145 (20): 2241–2242.

https://doi.org/10.1182/blood.2025028814

Published: 2025

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

Replication of associations between genetic polymorphisms and chronic graft-versus-host disease

Blood (2016) 128 (20): 2450–2456.

https://doi.org/10.1182/blood-2016-07-728063

Published: 2016

Includes: Supplemental data

Journal Articles

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Blood (2015) 125 (13): 2068–2074.

https://doi.org/10.1182/blood-2014-12-615187

Published: 2015

Includes: Supplemental data

Journal Articles

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

Corey Cutler, Brent Logan, Ryotaro Nakamura, Laura Johnston, Sung Choi, David Porter, William J. Hogan, Marcelo Pasquini, Margaret L. MacMillan, Jack W. Hsu, Edmund K. Waller, Stephan Grupp, Philip McCarthy, Juan Wu, Zhen-Huan Hu, Shelly L. Carter, Mary M. Horowitz, Joseph H. Antin

Blood (2014) 124 (8): 1372–1377.

https://doi.org/10.1182/blood-2014-04-567164

Published: 2014

Journal Articles

IMWG consensus on maintenance therapy in multiple myeloma

Blood (2012) 119 (13): 3003–3015.

https://doi.org/10.1182/blood-2011-11-374249

Published: 2012

Journal Articles

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission

David I. Marks, Tao Wang, Waleska S. Pérez, Joseph H. Antin, Edward Copelan, Robert Peter Gale, Biju George, Vikas Gupta, Joerg Halter, H. Jean Khoury, Thomas R. Klumpp, Hillard M. Lazarus, Victor A. Lewis, Philip McCarthy, David A. Rizzieri, Mitchell Sabloff, Jeff Szer, Martin S. Tallman, Daniel J. Weisdorf

Blood (2010) 116 (3): 366–374.

https://doi.org/10.1182/blood-2010-01-264077

Published: 2010

Includes: Supplemental data

Journal Articles

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Swaminathan Padmanabhan, MD, Anjana Elefante, PharmD, Prakash Varadarajan, MD, Minoo Battiwalla, MD, Arvinder Bir, MD, Theresa Hahn, PhD, Shannon Smiley, MD, Francisco J. Hernandez-Illizalitturi, MD, Loretta Miner, RNP, Alice Mohr, RNP, Zale P. Bernstein, MD, Asher Chanan-Khan, MD, Philip McCarthy, Jr., MD, Myron Czuczman, MD

Blood (2007) 110 (11): 5130.

https://doi.org/10.1182/blood.V110.11.5130.5130

Published: 2007

Journal Articles

Low Incidence of Deletions of ATM (ataxia-telangiectasia mutated) Gene in Patients (pts) with Multiple Myeloma (MM) as Detected by FISH.

Asher Alban Chanan-Khan, MD, Kena Miller, NP, Philip McCarthy, MD, Joanna M. Panasiewicz, AnneMarie W. Block, Ph.D.

Blood (2004) 104 (11): 4886.

https://doi.org/10.1182/blood.V104.11.4886.4886

Published: 2004

Journal Articles

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

Patrick Stiff, MD, Ivana Micallef, MD, Philip McCarthy, MD, Margarida Magalhaes-Silverman, MD, Neal Flomenberg, MD, Daniel Weisdorf, MD, Guido Tricot, MD, Mary Territo, MD, Rafat Abonour, MD, Karin Badel, Gary Calandra, MD/PhD

Blood (2004) 104 (11): 2847.

https://doi.org/10.1182/blood.V104.11.2847.2847

Published: 2004

Journal Articles

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Asher Alban Chanan-Khan, MD, Kena C. Miller, NP, Philip McCarthy, MD, Alexandra Koryzna, RN, Peter Kouides, MD, Kathleen Donohue, Alice Mohr, NP, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3463.

https://doi.org/10.1182/blood.V104.11.3463.3463

Published: 2004

Journal Articles

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Asher Alban Chanan-Khan, MD, Kena Miller, NP, Alexandra Koryzna, RN, Kenichi Takeshita, MD, Philip McCarthy, MD, Alice Mohr, NP, Kathleen Donohue, Zale P. Bernstein, MD, Arif Alam, MD, Myron S. Czuczman, MD

Blood (2004) 104 (11): 3476.

https://doi.org/10.1182/blood.V104.11.3476.3476

Published: 2004

Journal Articles

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

Myron S. Czuczman, MD, Marion Skipper, RN, Alice Mohr, NP, Zale P. Bernstein, MD, Philip McCarthy, MD, Francisco Hernandez-Ilizaliturri, MD, Asher Alban Chanan-Khan, MD

Blood (2004) 104 (11): 1396.

https://doi.org/10.1182/blood.V104.11.1396.1396

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Genomic determinants and differences of primary and secondary plasma cell leukemia

Peripheral blood immune profiling in newly diagnosed multiple myeloma: Associations with MRD status and high-risk cytogenetics

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Galectin-3 in host murine models lessens the severity of graft-versus-host disease by preserving intestinal stem cells irrespective of gut microbiota composition

Circulating immune profile in patients with amyloidosis

Germline genetic variants and post-HCT cytokine/chemokine milieu may identify those at higher risk of primary graft failure after allogeneic hematopoietic cell transplantation, a blood and marrow transplant clinical trials network (BMT CTN) study

Right time: stopping multiple myeloma maintenance

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Replication of associations between genetic polymorphisms and chronic graft-versus-host disease

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT

IMWG consensus on maintenance therapy in multiple myeloma

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first and second complete remission

Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.

Low Incidence of Deletions of ATM (ataxia-telangiectasia mutated) Gene in Patients (pts) with Multiple Myeloma (MM) as Detected by FISH.

AMD3100 Combined with Standard Doses of G-Csf Leads to Rapid, Consistent Mobilization of Hematopoietic Progenitor Cells in Patients with Non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma.

VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naïve Multiple Myeloma (MM).

Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naïve Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.

Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only